0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Cyclosporine's acceptance heralds new era in immunopharmacology

JAMA. 1983;250(4):449-450. doi:10.1001/jama.1983.03340040003001.
Text Size: A A A
Published online

ABSTRACT

From its modest beginning as a metabolite of a newly discovered fungus from Norway, cyclosporine has made its way steadily to medical prominence as the prototype of a new generation of immunopharmacologic agents.

"It must be pointed out that cyclosporine is no panacea," says immunologist Jean F. Borel, PhD, of Sandoz Ltd, in Basel, Switzerland, who discovered the agent's immunosuppressive properties in 1972. "It has nevertheless been shown to be the most potent and specific immunosuppressant so far discovered and to have an acceptable incidence of side effects."

Since 1978, numerous clinical trials have demonstrated that cyclosporine is as good as or significantly better than the conventional azathioprine-prednisone therapy used by most (solid) organ transplantation teams. In general, transplant recipients given cyclosporine retain their grafts longer and have fewer rejection episodes and serious infections than patients given conventional therapy.

Although concomitant prednisone therapy is necessary to help suppress macrophage-mediated immunity

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();